PTEN Mutation is an inclusion criterion in 45 clinical trials for malignant solid tumor, of which 33 are open and 12 are closed. Of the trials that contain PTEN Mutation and malignant solid tumor as inclusion criteria, 19 are phase 1 (11 open), 10 are phase 1/phase 2 (7 open), and 16 are phase 2 (15 open) [5].

PTEN Mutation is an inclusion criterion in 29 clinical trials for breast carcinoma, of which 23 are open and 6 are closed. Of the trials that contain PTEN Mutation and breast carcinoma as inclusion criteria, 8 are phase 1 (5 open), 6 are phase 1/phase 2 (4 open), 13 are phase 2 (12 open), and 2 are phase 3 (2 open) [5].

PTEN Mutation is an inclusion criterion in 14 clinical trials for prostate carcinoma, of which 7 are open and 7 are closed. Of the trials that contain PTEN Mutation and prostate carcinoma as inclusion criteria, 5 are phase 1 (1 open), 2 are phase 1/phase 2 (1 open), 5 are phase 2 (3 open), and 2 are phase 3 (2 open) [5].

PTEN Mutation is an inclusion criterion in 12 clinical trials for ovarian carcinoma, of which 7 are open and 5 are closed. Of the trials that contain PTEN Mutation and ovarian carcinoma as inclusion criteria, 3 are phase 1 (1 open), 3 are phase 1/phase 2 (2 open), 5 are phase 2 (4 open), and 1 is phase 3 (0 open) [5].

PTEN Mutation is an inclusion criterion in 11 clinical trials for non-small cell lung carcinoma, of which 5 are open and 6 are closed. Of the trials that contain PTEN Mutation and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (0 open), 6 are phase 1/phase 2 (3 open), and 3 are phase 2 (2 open) [5].

PTEN Mutation is an inclusion criterion in 10 clinical trials for prostate adenocarcinoma, of which 8 are open and 2 are closed. Of the trials that contain PTEN Mutation and prostate adenocarcinoma as inclusion criteria, 9 are phase 2 (7 open) and 1 is phase 3 (1 open) [5].

PTEN Mutation is an inclusion criterion in 7 clinical trials for head and neck squamous cell carcinoma, of which 3 are open and 4 are closed. Of the trials that contain PTEN Mutation and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (0 open), 4 are phase 1/phase 2 (2 open), and 2 are phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 7 clinical trials for small cell lung carcinoma, of which 5 are open and 2 are closed. Of the trials that contain PTEN Mutation and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 4 are phase 1/phase 2 (4 open), and 2 are phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 6 clinical trials for colorectal carcinoma, of which 3 are open and 3 are closed. Of the trials that contain PTEN Mutation and colorectal carcinoma as inclusion criteria, 3 are phase 1 (1 open) and 3 are phase 1/phase 2 (2 open) [5].

PTEN Mutation is an inclusion criterion in 6 clinical trials for endometrial carcinoma, of which 4 are open and 2 are closed. Of the trials that contain PTEN Mutation and endometrial carcinoma as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 6 clinical trials for primary peritoneal carcinoma, of which 3 are open and 3 are closed. Of the trials that contain PTEN Mutation and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [5].

PTEN Mutation is an inclusion criterion in 5 clinical trials for fallopian tube carcinoma, of which 2 are open and 3 are closed. Of the trials that contain PTEN Mutation and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [5].

PTEN Mutation is an inclusion criterion in 5 clinical trials for melanoma, of which 3 are open and 2 are closed. Of the trials that contain PTEN Mutation and melanoma as inclusion criteria, 2 are phase 1 (0 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 5 clinical trials for squamous cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain PTEN Mutation and squamous cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (0 open), and 1 is no phase specified (1 open) [5].

PTEN Mutation is an inclusion criterion in 4 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 1 is closed. Of the trials that contain PTEN Mutation and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 1/phase 2 (3 open) [5].

PTEN Mutation is an inclusion criterion in 4 clinical trials for non-hodgkin lymphoma, of which 3 are open and 1 is closed. Of the trials that contain PTEN Mutation and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [5].

PTEN Mutation is an inclusion criterion in 4 clinical trials for pancreatic adenocarcinoma, of which 3 are open and 1 is closed. Of the trials that contain PTEN Mutation and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [5].

PTEN Mutation is an inclusion criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PTEN Mutation and urothelial carcinoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 3 clinical trials for gastric adenocarcinoma, of which 1 is open and 2 are closed. Of the trials that contain PTEN Mutation and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 1/phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 3 clinical trials for gastric carcinoma, of which 2 are open and 1 is closed. Of the trials that contain PTEN Mutation and gastric carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 1/phase 2 (2 open) [5].

PTEN Mutation is an inclusion criterion in 3 clinical trials for osteosarcoma, of which 3 are open and 0 are closed. Of the trials that contain PTEN Mutation and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 3 clinical trials for soft tissue sarcoma, of which 3 are open and 0 are closed. Of the trials that contain PTEN Mutation and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 2 clinical trials for clear cell renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN Mutation and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN Mutation and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].

PTEN Mutation is an inclusion criterion in 2 clinical trials for Ewing sarcoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN Mutation and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain PTEN Mutation and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 2 clinical trials for glioblastoma, of which 0 are open and 2 are closed. Of the trials that contain PTEN Mutation and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (0 open) [5].

PTEN Mutation is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN Mutation and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN Mutation and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 2 clinical trials for leiomyosarcoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN Mutation and leiomyosarcoma as inclusion criteria, 2 are phase 2 (2 open) [5].

PTEN Mutation is an inclusion criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain PTEN Mutation and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [5].

PTEN Mutation is an inclusion criterion in 2 clinical trials for myeloid neoplasm, of which 2 are open and 0 are closed. Of the trials that contain PTEN Mutation and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN Mutation and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN Mutation and renal cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].

PTEN Mutation is an inclusion criterion in 2 clinical trials for undifferentiated pleomorphic sarcoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN Mutation and undifferentiated pleomorphic sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for aggressive systemic mastocytosis, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and aggressive systemic mastocytosis as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for angiosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and angiosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for bannayan syndrome, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and bannayan syndrome as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for breast adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and breast adenocarcinoma as inclusion criteria, 1 is phase 3 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for breast lobular carcinoma in situ, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and breast lobular carcinoma in situ as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and cancer as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and cervical carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for classical hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and classical hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for cowden syndrome, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and cowden syndrome as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for desmoid-type fibromatosis, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and desmoid-type fibromatosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for extraskeletal osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and extraskeletal osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for hematologic and lymphocytic disorder, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and hematologic and lymphocytic disorder as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and hematopoietic and lymphoid system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for hereditary breast and ovarian cancer syndrome, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and hereditary breast and ovarian cancer syndrome as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and malignant glioma as inclusion criteria, 1 is early phase 1 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for mast cell leukemia, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and mast cell leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for myxofibrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and myxofibrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for oropharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for ovarian clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and ovarian clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for pecoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and pecoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains PTEN Mutation and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for pleomorphic liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and pleomorphic liposarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for pleomorphic rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and pleomorphic rhabdomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for proteus syndrome, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and proteus syndrome as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 1 is phase 1 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PTEN Mutation is an inclusion criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN Mutation and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].